Procollagen 1 expression in atypical fibroxanthoma and other tumors

Journal of Cutaneous Pathology

Volumn 31, Issue 1, 2004, Pages 57-61

  Jensen, Kristin ^a   Wilkinson, Barbara ^b   Wines, Nina ^b   Kossard, Steven ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b SKIN AND CANCER FOUNDATION AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 17; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; CYTOKERATIN 8; KERATIN ANTIBODY; PROCOLLAGEN; PROCOLLAGEN 1; PROCOLLAGEN 1 ANTIBODY; PROTEIN ANTIBODY; PROTEIN S 100; PROTEIN S 100 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FIBROXANTHOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MORPHOLOGY; PROTEIN EXPRESSION; SKIN TUMOR; SPINDLE CELL; SQUAMOUS CELL CARCINOMA; SWEAT GLAND CARCINOMA; TISSUE SECTION; TRICHOEPITHELIOMA; TUMOR CELL;

ADULT; AGED; COLLAGEN TYPE I; FEMALE; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; XANTHOMATOSIS;

EID: 1642481115     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0303-6987.2004.0145.x     Document Type: Article

References (9)

1. Kauppila S, Saarela J, Stenbäck F, Risteli J, Kauppila A, Risteli L. Expression of mRNAs for type I and type II procollagens in serous ovarian cystadenomas and cystadenocarcinomas. Am J Pathol 1996; 148: 539.
2. Riekki R, Parikka M, Jukkola A, Salo T, Risteli J, Oikarinen A. Increased expression of collagen types I and III in human skin as a consequence of radiotherapy. Arch Dermatol Res 2002; 294: 178.
3. Varani J, Perone P, Fligiel SEG, Fisher GJ, Voorhees JJ. Inhibition of Type I procollagen production in photodamage: correlation between presence of high molecular weight collagen fragments and reduced procollagen synthesis. J Invest Dermatol 2002; 119: 122.
4. Mar N, Ruben B, McCalmont T. Procollagen I: a useful immunoperoxidase reagent for the diagnosis of atypical fibroxanthoma. J Cutan Pathol 2002; 29: 577 [Abstract].
5. Moy RL, Moy LS, Matsuoka LY, Bennett RG, Uitto J. Selectively enhanced procollagen gene expression in sclerosing (morphea-like) basal cell carcinoma as reflected by elevated Proα1(I) and Proα1(III) procollagen messenger RNA steadystate levels. J Invest Dermatol 1988; 90: 634.
6. Kauppila S, Stenbäck F, Kacinski BM, Carcangiu M, Risteli J, Risteli L. Characterization of type I collagen synthesis and maturation in uterine carcinosarcomas. Cancer 1999; 86: 1299.
7. Kauppila S, Stenbäck F, Risteli J, Jukkola A, Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol 1998; 186: 262.
8. Dahlman T, Lammerts E, Bergström D, et al. Collagen type I expression in experimental anaplastic thyroid carcinoma: regulation and relevance for tumorigenecity. Int J Cancer 2002; 98: 186.
9. Gray Y, Robidoux HJ, Farrell DS, Robinson-Bostom L. Squamous cell carcinoma detected by high-molecular-weight cytokeratin immunostaining mimicking atypical fibroxanthoma. Arch Pathol Lab Med 2001; 125: 799.